FAPI-Negative FDG-Avid Metastatic Relapse of Breast Cancer on PET/CT.
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
01 Aug 2023
01 Aug 2023
Historique:
medline:
3
7
2023
pubmed:
23
5
2023
entrez:
23
5
2023
Statut:
ppublish
Résumé
A 69-year-old woman with breast cancer underwent 18 F-FDG PET/CT because of the increased CA-15-3 level. 18 F-FDG PET/CT showed multiple hypermetabolic lymph nodes (LNs) in the neck and mediastinum. The patient was also referred for 68 Ga-fibroblast activation protein inhibitor (FAPI) 04 PET/CT for further evaluation. However, 18 F-FDG-avid LNs were FAPI-negative on 68 Ga-FAPI-04 PET/CT. Supraclavicular LN biopsy confirmed the metastasis of breast cancer. Recent reports have focused on the potential of FAPI PET imaging in breast cancer; however, this case highlights that false-negative 68 Ga-FAPI-04-PET/CT findings should also be considered while evaluating metastatic spread.
Identifiants
pubmed: 37220240
doi: 10.1097/RLU.0000000000004704
pii: 00003072-202308000-00035
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Gallium-68
98B30EPP5S
abamectin
5U8924T11H
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e380-e381Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest and sources of funding: none declared.
Références
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin . 2021;71:209–249.
Gennari A, André F, Barrios CH, et al. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol . 2021;32:1475–1495.
Han S, Choi JY. Impact of 18 F-FDG PET, PET/CT, and PET/MRI on staging and management as an initial staging modality in breast cancer: a systematic review and meta-analysis. Clin Nucl Med . 2021;46:271–282.
Groheux D. FDG-PET/CT for primary staging and detection of recurrence of breast cancer. Semin Nucl Med . 2022;52:508–519.
Has Şimşek D, Şanli Y, Külle CB, et al. Correlation of 18 F-FDG PET/CT with pathological features and survival in primary breast cancer. Nucl Med Commun . 2017;38:694–700.
Kuyumcu S, Sanli Y, Subramaniam RM. Fibroblast-activated protein inhibitor PET/CT: cancer diagnosis and management. Front Oncol . 2021;11:758958.
Kuyumcu S, Kovan B, Sanli Y, et al. Safety of fibroblast activation protein-targeted radionuclide therapy by a low-dose dosimetric approach using 177 Lu-FAPI04. Clin Nucl Med . 2021;46:641–646.
Rathke H, Fuxius S, Giesel FL, et al. Two tumors, one target: preliminary experience with 90 Y-FAPI therapy in a patient with metastasized breast and colorectal cancer. Clin Nucl Med . 2021;46:842–844.
Zheng S, Lin J, Zhu Y, et al. 68 Ga-FAPI versus 18 F-FDG PET/CT in evaluating newly diagnosed breast cancer patients: a head-to-head comparative study. Clin Nucl Med . 2023;48:e104–e109.
Wegen S, Roth KS, Weindler J, et al. First clinical experience with [ 68 Ga]Ga-FAPI-46-PET/CT versus [ 18 F]F-FDG PET/CT for nodal staging in cervical cancer. Clin Nucl Med . 2023;48:150–155.
Çermik TF, Ergül N, Yilmaz B, et al. Tumor imaging with 68 Ga-DOTA-FAPI-04 PET/CT: comparison with 18 F-FDG PET/CT in 22 different cancer types. Clin Nucl Med . 2022;47:e333–e339.
Kömek H, Can C, Güzel Y, et al. (68)Ga-FAPI-04 PET/CT, a new step in breast cancer imaging: a comparative pilot study with the (18)F-FDG PET/CT. Ann Nucl Med . 2021;35:744–752.
Ding F, Huang C, Liang C, et al. (68)Ga-FAPI-04 vs. (18)F-FDG in a longitudinal preclinical PET imaging of metastatic breast cancer. Eur J Nucl Med Mol Imaging . 2021;49:290–300.
Zheng S, Chen Y, Zhu Y, et al. Both [(68)Ga]Ga-FAPI and [(18)F]FDG PET/CT missed bone metastasis in a patient with breast cancer. Eur J Nucl Med Mol Imaging . 2021;48:4519–4520.